Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
Stocks · News reference
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Shares of Iovance Biotherapeutics are trading slightly lower Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11
Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call
Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you
8-K filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Filed: 2026-10-05 AccNo: 0001104659-26-113763 Size: 21 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits